Tuesday, 20 Mar 2018

You are here

Infliximab Does Not Increase Perioperative Infection

Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (https://buff.ly/2iBFVjp).  On the other hand, discontinuation of the TNFi prior to surgery is associated with lower rates of  infection (https://buff.ly/2iAFZQf)

George and colleagues analyzed the timing of inflixiamb discontinuation before elective arthroplasty and found that infliximab given within 4 weeks of elective knee or hip arthroplasty was not associated with a higher risk of short  or long-term serious infection. 

Infection risk was primarily associated with glucocorticoid use, especially >10 mg/day. The 30-day infection risk was double for short term infection (OR 2.11; 95% CI 1.30–3.40) and long term prosthetic infections (HR 2.70; 95% CI 1.30–5.60). Other risk factors for infection included elderly age, comorbidities, revision surgery, and previous hospitalized infection.

They examined infliximab patients hospitalized for infection (within 30 days) and found an event rate of 6.3% (270 out of 4,288 surgeries) They then compared infliximab use - those stopping infliximab <4 weeks of surgery and compared this cohort to those stopping infliximab versus longer 8–12 weeks.  The overall infection rate did not differ between groups and the long term prosthetic infection rates were also similar between group (2.9 per 100 person-years).



Add new comment

More Like This

Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept

The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

Obesity Outweighs Psoriasis in Comorbidity Risk with Children

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

Using claims data from Optum Laboratories Data Warehouse (150 million privately insured and Medicare enrollees), of 29 957 children with psoriasis were matched with a comparator cohort (children without psoriasis) and studied for the effects of psoriasis and obsesity. 

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients. 

PRESERVE Study: HAQ, BMI and Age Predict Responses to Combo Therapy

Rheumatoid arthritis patients who were younger and who had lower body mass index, Health Assessment Questionnaire (HAQ) scores, and less disease activity at baseline were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, a post hoc analysis of the PRESERVE trial found.